NAMS
Income statement / Annual
Last year (2024), NewAmsterdam Pharma Company N.V.'s total revenue was $45.56 M,
an increase of 257.00% from the previous year.
In 2024, NewAmsterdam Pharma Company N.V.'s net income was -$241.60 M.
See NewAmsterdam Pharma Company N.V.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$45.56 M |
$12.76 M |
$95.91 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$45.56 M
|
$12.76 M
|
$95.91 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
0
|
0
|
| Research and Development Expenses |
$151.41 M
|
$159.42 M
|
$81.01 M
|
$25.46 M
|
$4.05 M
|
| General & Administrative Expenses |
$70.45 M
|
$25.72 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$4.06 M
|
$1.60 M
|
$858,392.00
|
$11,000.00
|
| Selling, General & Administrative Expenses |
$70.45 M
|
$29.77 M
|
$18.22 M
|
$5.27 M
|
$1.38 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$221.85 M
|
$197.06 M
|
$116.78 M
|
$36.35 M
|
$5.40 M
|
| Cost And Expenses |
$221.85 M
|
$183.23 M
|
$116.78 M
|
$36.35 M
|
$5.40 M
|
| Interest Income |
$16.88 M
|
$10.22 M
|
$268,029.00
|
$361,104.00
|
$344,000.00
|
| Interest Expense |
$0.00
|
$6.80 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
-$65.20 M
|
$49,000.00
|
$8,405.00
|
$4,393.00
|
$1,000.00
|
| EBITDA |
-$241.49 M |
-$176.86 M |
-$3.31 M |
-$30.73 M |
-$5.43 M |
| EBITDA Ratio |
-5.3
|
-13.86
|
-0.03
|
0
|
0
|
| Operating Income Ratio |
-3.87
|
-12.99
|
-0.03
|
0
|
0
|
| Total Other Income/Expenses Net |
-$65.31 M
|
$5.49 M
|
-$17.58 M
|
-$5.98 M
|
-$320,000.00
|
| Income Before Tax |
-$241.60 M
|
-$160.25 M
|
-$21.14 M
|
-$36.71 M
|
-$5.75 M
|
| Income Before Tax Ratio |
-5.3
|
-12.56
|
-0.22
|
0
|
0
|
| Income Tax Expense |
-$1,000.00
|
$27,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$241.60 M
|
-$176.94 M
|
-$21.14 M
|
-$36.71 M
|
-$5.75 M
|
| Net Income Ratio |
-5.3
|
-13.86
|
-0.22
|
0
|
0
|
| EPS |
-2.56 |
-2.15 |
-1.11 |
-3.34 |
-1.15 |
| EPS Diluted |
-2.56 |
-2.15 |
-1.11 |
-3.34 |
-1.15 |
| Weighted Average Shares Out |
$94.36 M
|
$82.16 M
|
$18.97 M
|
$17.75 M
|
$17.75 M
|
| Weighted Average Shares Out Diluted |
$94.36 M
|
$82.16 M
|
$18.97 M
|
$17.75 M
|
$17.75 M
|
| Link |
|
|
|
|
|
